Ambrisentan · Letairis

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Pulmonary arterial hypertension (Volibris 2.5 mg, GlaxoSmithKline K.K.)
Product first approved 2010pj.jiho.jp
EU
  • Pulmonary arterial hypertension in adults (authorised as Volibris, marketed by GSK under licence from Gilead; same asset as Letairis, separate EU application)
Product first approved 2008EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Pulmonary Arterial Hypertension
NCT07245680 · Assistance Publique - Hôpitaux de Paris
2026-04-28 – 2029-02-14 · Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)
What this study did
NCT00578786 · Gilead Sciences
2004-02 – 2010-03 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT01224210 · Tufts Medical Center
2010-03 – 2020-03 · Portopulmonary Hypertension
What this study did
NCT00777920 · Gilead Sciences
2008-11-17 – 2019-09-11 · Pulmonary Hypertension
What this study did
NCT01884675 · GlaxoSmithKline
2013-09 – 2015-03 · Hypertension
What this study did
NCT00879229 · Gilead Sciences
2009-07 – 2011-02 · Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
What this study did
NCT00768300 · Gilead Sciences
2008-12 – 2011-02 · Idiopathic Pulmonary Fibrosis
What this study did
NCT00380068 · Gilead Sciences
2006-08 – 2009-05 · Pulmonary Hypertension
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT04393246 · Cambridge University Hospitals NHS Foundation Trust
2020-07-03 – 2022-06-08 · COVID-19
What this study did
NCT01902758 · University of Montana
2013-08 – 2013-08 · Acute Mountain Sickness
What this study did
NCT01352065 · Center for Health Sciences, Serbia
2011-01 – 2013-05 · Pulmonary Hypertension
What this study did
NCT00851929 · Medical University of South Carolina
2008-11 – 2011-11 · Sarcoidosis, Pulmonary Hypertension
What this study did
Phase 2 (11)
Pulmonary Arterial Hypertension
NCT02290613 · Heidelberg University
2014-07-01 – 2017-12-31 · Systemic Sclerosis, Pulmonary Hypertension
What this study did
NCT00424021 · Gilead Sciences
2003-04 – 2009-12 · Pulmonary Hypertension
What this study did
NCT00423592 · Gilead Sciences
2005-05 – 2009-03 · Pulmonary Hypertension
What this study did
Other / comorbidity
NCT06256432 · Noorik Biopharmaceuticals AG
2024-04-17 – 2026-06 · Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
What this study did
NCT04771000 · Noorik Biopharmaceuticals AG
2021-02-08 – 2023-02-27 · Covid19, Hypoxemia
What this study did
NCT01342952 · GlaxoSmithKline
2011-06-21 – 2022-06-09 · Hypertension, Pulmonary
What this study did
NCT03827200 · Noorik Biopharmaceuticals AG
2019-04-11 – 2021-01-21 · Cirrhosis, Portal Hypertension, Ascites
What this study did
NCT04450095 · Bnai Zion Medical Center
2018-10-11 – 2020-10-01 · Kidney Failure, Acute
What this study did
NCT02080637 · Kevin Hill
2015-07 – 2017-08-20 · Hypoplastic Left Heart Syndrome, Hypoplastic Right-sided Heart Complex
What this study did
NCT01617746 · University of Glasgow
2012-11 – 2015-12 · Asthma
What this study did
NCT01332331 · GlaxoSmithKline
2011-01-04 – 2013-11-12 · Hypertension, Pulmonary
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01733095 · Medical University of Graz
2012-07 – 2016-06 · Portopulmonary Hypertension
What this study did
Phase 1 (4)
Other / comorbidity
NCT04095286 · GlaxoSmithKline
2019-09-30 – 2019-12-17 · Hypertension, Pulmonary
What this study did
NCT02712346 · Augusta University
2015-09 – 2019-11-30 · Sickle Cell Anemia
What this study did
NCT02688387 · GlaxoSmithKline
2016-03-18 – 2017-08-04 · Hypertension, Pulmonary
What this study did
NCT01794078 · Robert J Noveck, M.D.
2013-09 – 2014-12 · Acute Mountain Sickness and Fatigue
What this study did
Phase 4 (11)
Pulmonary Arterial Hypertension
NCT02253394 · Brigham and Women's Hospital
2015-09 – 2018-02 · Pulmonary Arterial Hypertension
What this study did
NCT02885012 · Medical University of South Carolina
2016-06 – 2017-07-07 · Pulmonary Arterial Hypertension
What this study did
NCT01338636 · Brigham and Women's Hospital
2008-09 – 2016-05 · Exercise-induced Pulmonary Arterial Hypertension
What this study did
NCT01042158 · Johns Hopkins University
2010-01 – 2014-11 · Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
What this study did
NCT01330108 · University of Alabama at Birmingham
2011-05 – 2012-06 · Pulmonary Arterial Hypertension
What this study did
NCT00617305 · Gilead Sciences
2008-04 – 2011-07 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07030894 · The First Hospital of Jilin University
2025-09-01 – 2026-12-31 · IgA Nephropathy, Chronic Kidney Disease, Proteinuria
What this study did
NCT03309592 · Ochsner Health System
2017-10-12 – 2018-11-01 · Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
What this study did
NCT01971580 · Washington University School of Medicine
2012-08 – 2015-05 · Single Ventricle Fontan Palliation
What this study did
NCT00840463 · University of Texas Southwestern Medical Center
2009-01 – 2014-01 · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
What this study did
NCT01051960 · University of California, Los Angeles
2009-03 – 2011-01 · Systemic Sclerosis, Shortness of Breath, Pulmonary Hypertension
What this study did
Early phase / not applicable (8)
Pulmonary Arterial Hypertension
NCT06987097 · Nanjing First Hospital, Nanjing Medical University
2025-05-15 – 2029-03-01 · Pulmonary Arterial Hypertension (PAH)
What this study did
NCT06968962 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-05-14 – 2028-12 · Pulmonary Arterial Hypertension (PAH)
What this study did
NCT04972656 · Nanjing First Hospital, Nanjing Medical University
2022-09-05 – 2026-03-30 · Pulmonary Arterial Hypertension
What this study did
NCT02169752 · National Jewish Health
2012-09 – 2017-05-25 · Pre-Pulmonary Atrial Hypertension
What this study did
NCT02958358 · Robert Scott Harris, M.D.
2014-09 – 2016-09 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT01093885 · University of Pennsylvania
2010-02 – 2016-07 · Systemic Sclerosis, Scleroderma
What this study did
NCT01072669 · Soumya Chatterjee
2010-02 – 2010-12 · Ischemia
What this study did
NCT00725361 · Stanford University
2008-06 – 2010-12 · n Ulcer, Scleroderma, Systemic
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1/2 (1)
Pulmonary Arterial Hypertension
NCT04528056 · RenJi Hospital
2020-08-01 – 2022-10-31 · Pulmonary Arterial Hypertension
What this study did
Phase 1 (1)
Other / comorbidity
NCT01530464 · Thies Schroeder
2012-02 – 2012-04 · High Altitude Pulmonary Hypertension
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Other / comorbidity
NCT07844213 · China National Center for Cardiovascular Diseases
2022-08-25 – 2025-08-31 · Congenital Heart Disease, Pulmonary Hypertension
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ambrisentan (Letairis): this drugApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Atrasentan (Vanrafia)
Approved(overall)
Small moleculeEndothelin A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Zibotentan + Dapagliflozin
Phase 3(overall)
Small moleculeEndothelin A receptor, SGLT2
not yet graded(overall)
No reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Letairis (Ambrisentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4IgA Nephropathy, Chronic Kidney Disease, ProteinuriaRecruiting
Est. primary completion 2026-12-31 · NCT07030894 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Early phase / not applicablePulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-02-28 · NCT06987097 · CT.gov ↗
What to watch
May 2028 (1)
Early phase / not applicablePulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-05 · NCT06968962 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 3Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2029-02-14 · NCT07245680 · CT.gov ↗
What to watch

See the full readout calendar ↗